Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review synthesizes evidence on the prevalence, impacts, causes, and treatment of erectile dysfunction in men under 40 but reports no new clinical results; the authors emphasize the need for comprehensive evaluation and individualized care.

The Princeton III Consensus recommends assessing cardiovascular risk in men with erectile dysfunction and prioritizing heart health before treating ED, especially in those with potential heart disease.

This review discusses the increasing prevalence of erectile dysfunction in young men and emphasizes the importance of identifying specific causes for effective management, reporting no new clinical results.

This study found that 5-α reductase inhibitors do not significantly increase the risk of erectile dysfunction in men with benign prostatic hyperplasia or alopecia, although duration of benign prostatic hyperplasia may elevate risk.

This study found that long-term dutasteride therapy in men with benign prostatic hyperplasia worsened erectile dysfunction, reduced testosterone levels, and increased blood glucose and lipid profile, indicating negative metabolic impacts.

This case study concluded that weight loss is the initial recommended approach for treating secondary hypogonadism, as shown by improvements in testosterone levels and symptoms in an obese 37-year-old patient.

This article updates the process of care model for evaluating erectile dysfunction, emphasizing comprehensive evaluation and a combination of pharmacotherapy and counseling tailored to patient dynamics.

This study found no significant benefit of platelet-rich plasma injections over placebo in improving erectile function in patients with mild to moderate erectile dysfunction.

Men's age, urinary symptoms, and heart health risks create different types of erectile dysfunction.

This study observed enduring sexual dysfunction reported in 300 cases globally following the use of SSRIs, finasteride, and isotretinoin, with common symptoms like genital anaesthesia and loss of libido.

In this study, 96% of men with persistent sexual side effects from finasteride reported continued dysfunction after discontinuation, suggesting these effects may endure long-term.

This review examines reports of prolonged sexual dysfunction and depression associated with finasteride for male pattern hair loss, concluding that significant biases exist and further rigorous trials are needed to assess risks.

In this article, Irwig reported that sexual side effects of finasteride persist in 96% of patients even after stopping the medication, raising concerns about potential permanence.

This study found that 5-α reductase inhibitors and neuropsychiatric medications were most frequently reported for erectile dysfunction in a national pharmacovigilance database from 2010 to 2020.

This review discusses the adverse effects of 5α-reductase inhibitors, finasteride and dutasteride, on sexual, psychological, and vascular health, emphasizing the need for physicians to inform patients of these risks.

This study found that 5α-reductase inhibitors significantly increase the risk of erectile dysfunction and hypoactive sexual desire in men with benign prostatic hyperplasia, compared to placebo.

This study found that in men with sexual dysfunction, use of 5ARI may reduce sexual drive and spontaneous erections without worsening pre-existing erectile or ejaculatory issues.

This article reports that the rise in erectile dysfunction among young men may be linked to mental health issues and societal pressures, with online communities often encouraging risky substance use like anabolic steroids and finasteride, which can exacerbate psychological and physical health problems.

This hypothesis paper suggests that sexual and cognitive dysfunctions reported by some men after using finasteride and dutasteride may stem from vascular and tissue changes in penile tissue triggering broader inflammatory effects.

This study evaluated the persistent adverse effects of 5α-reductase inhibitors in men previously treated for androgenic alopecia and highlighted issues with sexual, genitourinary, physical, psychiatric, cognitive, and androgenic health.

Finasteride's sexual side effects not caused by androgen deficiency or SRD5A inhibition.

This study found no significant evidence supporting the effectiveness of platelet-rich plasma injections for treating mild-to-moderate erectile dysfunction compared to placebo.

This paper describes the development of diagnostic criteria for several enduring sexual dysfunction conditions following the use of certain medications, highlighting common sexual and non-sexual symptoms.

Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.

This study found that patients with post-finasteride syndrome exhibited major depressive disorder, severe erectile dysfunction, and neuropathy, alongside altered neuroactive steroid levels in cerebrospinal fluid.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.

This study concluded that 5α-reductase inhibitors were linked to increased sexual dysfunction in men with benign prostatic hyperplasia, but not in men with androgenetic alopecia.

This review discusses the negative health impacts of testosterone deficiency and the potential adverse effects of 5α-reductase inhibitors, emphasizing the need for patient-physician discussions regarding these treatments.

This meta-analysis found that treating male androgenetic alopecia with 5α-reductase inhibitors increases the risk of sexual dysfunction, with a statistically significant risk for finasteride but not for dutasteride.

This review discusses the neurobiology of sexual function and reports no new results; the authors cover multiple endocrine and neurotransmitter influences on sexual desire, arousal, and orgasm stages.